Document Detail


Early versus late injection medialization for unilateral vocal cord paralysis.
MedLine Citation:
PMID:  20824787     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate whether the timing of early (≤6 months from time of nerve injury) vs. late (>6 months) injection medialization laryngoplasty impacts the need for subsequent open-neck reconstruction to restore vocal function in patients with unilateral vocal cord paralysis. STUDY DESIGN: Retrospective chart review. METHODS: A total of 112 outpatient or hospitalized adults with dysphonia resulting from postsurgical or idiopathic unilateral vocal cord paralysis were identified who were injected as initial treatment within 1 year of onset of their paralysis. All subjects underwent awake, transoral, paraglottic injection with absorbable hyaluronic-acid gel. Patients with documented recovery of vocal cord mobility (22), active disease directly affecting the recurrent laryngeal nerve (8), <3 months of follow-up after injection (time for gel to be reabsorbed) (34), or deaths within 1 year after the onset of paralysis (13) were excluded, leaving a study population of 35 patients. RESULTS: Twenty of 32 (62.5%) patients with early injection medialization maintained an adequate voice, obviating the need for open-neck phonosurgical reconstruction; their follow-up from onset of paralysis ranged from 4.0 to 41.8 months (mean 15.2). None of the three patients undergoing late injection (>6 months postparalysis) avoided phonosurgical reconstruction (P = .03, χ2 test). CONCLUSIONS: Patients receiving early injection medialization for vocal cord paralysis were less likely to require transcervical reconstruction. We believe that early medialization creates a more favorable vocal cord position for phonation that can be maintained by synkinetic reinnervation, in contrast to the final position of a lateralized vocal cord being determined solely by reinnervation.
Authors:
Aaron D Friedman; James A Burns; James T Heaton; Steven M Zeitels
Related Documents :
21231997 - International quotidian dialysis registry: annual report 2010.
23709547 - Tricky brucellosis.
11215597 - Changes in vocal loudness following intensive voice treatment (lsvt) in individuals wit...
9102437 - Predictive assessment of vocal efficiency (pave). a method for voice therapy outcome me...
23354567 - A phase i trial of thermal sensitization using induced oxidative stress in the context ...
9288507 - Aortic dissection type a versus type b: a different post-surgical death hazard?
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Laryngoscope     Volume:  120     ISSN:  1531-4995     ISO Abbreviation:  Laryngoscope     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-29     Completed Date:  2010-10-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607378     Medline TA:  Laryngoscope     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2042-6     Citation Subset:  IM    
Affiliation:
Department of Surgery, Harvard Medical School, Center for Laryngeal Surgery and Voice Rehabilitation, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. afriedman3@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Female
Gels / administration & dosage
Humans
Hyaluronic Acid / administration & dosage*
Injections
Male
Middle Aged
Recurrent Laryngeal Nerve / physiopathology
Retrospective Studies
Time Factors
Treatment Outcome
Viscosupplements / administration & dosage*
Vocal Cord Paralysis / drug therapy*,  etiology,  physiopathology
Chemical
Reg. No./Substance:
0/Gels; 0/Viscosupplements; 9004-61-9/Hyaluronic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute airway obstruction in cervical spinal procedures with bone morphogenetic proteins.
Next Document:  Hearing loss alters quantal release at cochlear nucleus stellate cells.